Voting Rights and Shares Capital of the Company
Rhea-AI Summary
Nanobiotix (NASDAQ: NBTX) disclosed its voting rights and share count as of January 31, 2026. The company reported 48,450,358 shares outstanding, 50,153,460 theoretical voting rights and 50,131,342 exercisable voting rights.
The release explains methodology for theoretical vs exercisable voting rights and lists contact details for investor and media relations.
Positive
- None.
Negative
- None.
News Market Reaction – NBTX
In the Feb 18 session, NBTX gained 1.15%, reflecting a mild positive market reaction. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 13 | Voting-rights update | Neutral | +0.7% | Reported Dec 31, 2025 share count and theoretical/exercisable voting rights. |
| Dec 17 | Voting-rights update | Neutral | +3.1% | Disclosed Nov 30, 2025 voting-rights and share-capital figures under French rules. |
| Dec 15 | Index inclusion | Positive | -1.6% | Announced inclusion in CAC Mid 60 and SBF 120 indices on Euronext Paris. |
| Nov 24 | Ops/financial update | Positive | +5.1% | Detailed Q3 2025 update, royalty financing and extended cash visibility to early 2028. |
| Nov 14 | Voting-rights update | Neutral | +2.6% | Released Oct 31, 2025 share count and theoretical vs exercisable voting rights. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Routine voting-rights/share-capital disclosures have historically been followed by modestly positive moves, while more substantive operational updates have seen stronger reactions.
Over the last few months, NANOBIOTIX has alternated between routine capital/voting-rights notices and more substantial corporate milestones. Regular monthly disclosures on Oct 31, Nov 30, and Dec 31, 2025 each reported updated share and voting-rights counts with small positive price reactions. A major operational and financial update on Nov 24, 2025 outlining a $50 million royalty financing, additional $21 million contingent funds, and cash visibility into early 2028 drew a stronger positive move. Index inclusion news on Dec 15, 2025 saw a slight negative reaction, showing occasional divergence from upbeat headlines.
Key Terms
isin financial
voting rights regulatory
nanotechnology medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
PARIS, Feb. 17, 2026 (GLOBE NEWSWIRE) --
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: www.nanobiotix.com
| Date | Number of Shares Outstanding | Total number of voting rights | |
| Total voting rights, theoretical1 | Total voting rights, exercisable2 | ||
| January 31, 2026 | 48,450,358 | 50,153,460 | 50,131,342 |
About NANOBIOTIX
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.
Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.
Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.
For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.
________________________________
1 The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.
2 The total number of exercisable at a shareholders’ meeting (or “net”) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed.
Contacts
| Nanobiotix | |
| Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com | Investor Relations Department Joanne Choi VP, Investor Relations (US) +1 (713) 609-3150 Ricky Bhajun Director, Investor Relations (EU) investors@nanobiotix.com |
| Media Relations | |
| France – HARDY Caroline Hardy +33 06 70 33 49 50 carolinehardy@outlook.fr | Global – uncapped Becky Lauer +1 (646) 286-0057 uncappednanobiotix@uncappedcommunications.com |
Attachments
- 2026-02-17 -- NBTX -- Voting Rights & Shares Capital -- FINAL
